'Samsung Bio, Record-Breaking Performance, Surpasses 4.5 Trillion KRW in Sales Last Year'

Record-Breaking Performance
Sales Reach 4.5473 Trillion KRW, Operating Profit Hits 1.3201 Trillion KRW

Samsung Biologics' annual sales exceeded 4.5 trillion KRW last year. It is the first domestic pharmaceutical and bio company to surpass 4 trillion KRW in annual sales.

Samsung Biologics Plant 4. Samsung Biologics

Samsung Biologics announced on the 22nd through a public disclosure that its consolidated annual sales for 2024 reached 4.5473 trillion KRW, with an operating profit of 1.3201 trillion KRW. Compared to the previous year, sales increased by 23% (852.7 billion KRW) and operating profit rose by 19% (206.4 billion KRW).

On a standalone basis, Samsung Biologics' annual sales also approached 3.5 trillion KRW. Supported by increased sales from Plant 4 and full operation of Plants 1 to 3, sales reached 3.4971 trillion KRW, and operating profit was 1.3214 trillion KRW. Compared to the previous year, sales grew by 19% (558.3 billion KRW) and operating profit increased by 10% (117.2 billion KRW).

Samsung Bioepis also posted strong results. Samsung Bioepis recorded sales of 1.5377 trillion KRW and an operating profit of 435.4 billion KRW. Expanding the global market presence of its biosimilar products, sales increased by 51% (517.4 billion KRW) and operating profit rose by 112% (230 billion KRW) compared to the previous year.

Fourth-quarter sales also hit a record high. Samsung Biologics' consolidated sales for Q4 reached 1.2564 trillion KRW, a 17% (182.9 billion KRW) increase from the same period last year. However, operating profit slightly declined by about 7% to 325.7 billion KRW.

On a standalone basis, Samsung Biologics' sales increased by 15% (122.5 billion KRW) year-on-year to 950.4 billion KRW, driven by full operation of Plants 1 to 3 and increased sales from Plant 4. Operating profit decreased by 6% (19.3 billion KRW) compared to the same period last year, recording 314.7 billion KRW, due to investments aimed at strengthening CDMO capabilities.

Samsung Bioepis' sales rose by 38% (108.5 billion KRW) year-on-year to 397.4 billion KRW, driven by expanded sales of biosimilar products. Operating profit decreased by 8% (5.9 billion KRW) compared to the same period last year, recording 72.3 billion KRW, impacted by increased research and development expenses to establish a foundation for future growth.

This content was produced with the assistance of AI translation services.